Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Mallinckrodt
Express Scripts
Harvard Business School
McKinsey

Last Updated: November 26, 2022

CLINICAL TRIALS PROFILE FOR DESOGESTREL; ETHINYL ESTRADIOL


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Desogestrel; Ethinyl Estradiol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00204438 ↗ Administration of Oral Contraceptives at Different Times of the Follicular Phase of the Menstrual Cycle Completed Canadian Institutes of Health Research (CIHR) N/A 2002-02-01 We hypothesize that administration of OCs at varying follicular diameters will provide an appropriate model for the study of follicular atresia in women. Clinically, we hypothesize that the administration on OCs at different stages of the follicular phase will result in markedly different patterns of follicular development and/or atresia.
NCT00204438 ↗ Administration of Oral Contraceptives at Different Times of the Follicular Phase of the Menstrual Cycle Completed University of Saskatchewan N/A 2002-02-01 We hypothesize that administration of OCs at varying follicular diameters will provide an appropriate model for the study of follicular atresia in women. Clinically, we hypothesize that the administration on OCs at different stages of the follicular phase will result in markedly different patterns of follicular development and/or atresia.
NCT00439972 ↗ Oral Versus Patch Hormonal Contraceptive Effects on Metabolism, Clotting, Inflammatory Factors and Vascular Reactivity Unknown status Ortho-McNeil Pharmaceutical Phase 2 2007-02-01 The purpose of this study is to compare the effects of oral versus patch administration of hormonal contraception on hormone sensitive proteins such as lipoproteins, clotting factors and inflammatory proteins as well as blood sugar and insulin levels, antioxidant status and flow-mediated dilation of arm and forearm vessels. The hypothesis is that oral administration of contraceptive hormones will result in higher plasma levels of estrogen sensitive proteins originating from the liver while patch administration of contraceptive hormones will result in greater systemic effects of estrogen on vascular reactivity and antioxidant status.
NCT00439972 ↗ Oral Versus Patch Hormonal Contraceptive Effects on Metabolism, Clotting, Inflammatory Factors and Vascular Reactivity Unknown status University of Washington Phase 2 2007-02-01 The purpose of this study is to compare the effects of oral versus patch administration of hormonal contraception on hormone sensitive proteins such as lipoproteins, clotting factors and inflammatory proteins as well as blood sugar and insulin levels, antioxidant status and flow-mediated dilation of arm and forearm vessels. The hypothesis is that oral administration of contraceptive hormones will result in higher plasma levels of estrogen sensitive proteins originating from the liver while patch administration of contraceptive hormones will result in greater systemic effects of estrogen on vascular reactivity and antioxidant status.
NCT00612508 ↗ Hormonal Contraception and Vaginal Health Completed Oregon Clinical and Translational Research Institute N/A 2007-05-01 The purpose of this study is to help determine if the route by which women receive hormonal contraception causes different changes to occur in the lining of the vagina. The investigators plan to compare an oral route (taking birth control pills) with a vaginal route (using a vaginal ring).
NCT00612508 ↗ Hormonal Contraception and Vaginal Health Completed Oregon Health and Science University N/A 2007-05-01 The purpose of this study is to help determine if the route by which women receive hormonal contraception causes different changes to occur in the lining of the vagina. The investigators plan to compare an oral route (taking birth control pills) with a vaginal route (using a vaginal ring).
NCT01256619 ↗ Evaluation of an Oral Contraceptive Containing 30 mg Ethinyloestradiol and 150 mg Desogestrel on Women's Health Unknown status Tehran University of Medical Sciences Phase 2 2010-09-01 The desogestrel (150 mg) in combination with ethinyl estradiol (EE, 30 mg) is known as Marvelon in European countries. Previous studies revealed that the Marvelon is good and safe for women. As a study from Thailand showed that the Marvelon to be effective and acceptable in Thai women. Moreover compared to Caucasian women, the incidences of irregular bleeding and side effects were apparently lower in these Asian women . Although Marvelon was used in many countries but it's efficacy didn't reported among Iranian women.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Desogestrel; Ethinyl Estradiol

Condition Name

Condition Name for Desogestrel; Ethinyl Estradiol
Intervention Trials
Contraception 2
Acne Vulgaris 1
Bioequivalence 1
Contraceptive Usage 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Desogestrel; Ethinyl Estradiol
Intervention Trials
Acne Vulgaris 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Desogestrel; Ethinyl Estradiol

Trials by Country

Trials by Country for Desogestrel; Ethinyl Estradiol
Location Trials
United States 3
Canada 1
Thailand 1
Iran, Islamic Republic of 1
Chile 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Desogestrel; Ethinyl Estradiol
Location Trials
Pennsylvania 1
Oregon 1
Washington 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Desogestrel; Ethinyl Estradiol

Clinical Trial Phase

Clinical Trial Phase for Desogestrel; Ethinyl Estradiol
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 2 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Desogestrel; Ethinyl Estradiol
Clinical Trial Phase Trials
Completed 4
Unknown status 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Desogestrel; Ethinyl Estradiol

Sponsor Name

Sponsor Name for Desogestrel; Ethinyl Estradiol
Sponsor Trials
National Institutes of Health (NIH) 1
Anuja Dokras 1
Canadian Institutes of Health Research (CIHR) 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Desogestrel; Ethinyl Estradiol
Sponsor Trials
Other 9
Industry 3
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Express Scripts
McKinsey
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.